Amgen shares fall after Novartis' Pelacarsen misses Phase III goal

Amgen shares fall after Novartis' Pelacarsen misses Phase III goal: the analysis positions IONS, NVS and AMGN under pressure; confidence high.

Analyzed 2026-09-07 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Who's next

▼ IONS Ionis — impact -82 · confidence high · horizon immediate · 1st order
Ionis loses expected milestone and royalty income after its partner's pelacarsen trial fails to reduce cardiovascular events.
Chain: pelacarsen misses primary cardiovascular endpoint in Phase III → Novartis approval and launch path narrows sharply → Ionis milestone payments become unlikely → Ionis royalty stream on pelacarsen sales shrinks
What would break the call: Novartis files on subgroup or secondary benefit and regulators accept it, restoring milestone and royalty payments.
▼ NVS Novartis — impact -75 · confidence high · horizon immediate · 1st order
Novartis loses prospective cardiovascular revenue as pelacarsen fails its primary endpoint and weakens future cash flows.
Chain: Lp(a)HORIZON primary endpoint not met → pelacarsen loses probable cardiovascular prevention label → multibillion peak sales estimate leaves forecasts → Novartis cardiovascular pipeline value marked down
What would break the call: Full data at conference shows clear benefit in high Lp(a) subgroup and Novartis secures a filing.
▼ AMGN Amgen — impact -72 · confidence high · horizon immediate · 2nd order
Amgen's olpasiran loses commercial value as pelacarsen's failure undermines confidence that Lp(a) reduction prevents cardiovascular events.
Chain: rival pelacarsen fails to cut cardiovascular events → Lp(a) lowering hypothesis loses clinical validation → olpasiran outcomes trial success probability falls → Amgen pipeline value and launch revenue discounted
What would break the call: OCEAN(a) outcomes data later shows event reduction with deeper and more durable Lp(a) lowering.
▼ SLN Silence Therapeutics — impact -70 · confidence medium · horizon immediate · 3rd order
Silence Therapeutics faces weaker zerlasiran licensing prospects because pelacarsen's outcomes failure makes partners demand stronger evidence.
Chain: pelacarsen outcomes failure weakens Lp(a) target thesis → large pharma partners raise evidence bar → zerlasiran licensing terms and upfronts deteriorate → Silence financing and cash runway pressure increases
What would break the call: Silence announces a funded partnership with a large upfront despite the pelacarsen result.
▼ ALNY Alnylam — impact -35 · confidence medium · horizon weeks · 3rd order
Alnylam's royalty income declines as pelacarsen's failure shrinks the commercial opportunity for olpasiran.
Chain: olpasiran commercial opportunity shrinks after class setback → Alnylam siRNA royalty base on olpasiran narrows → future platform royalty income estimates decline
What would break the call: Amgen reaffirms OCEAN(a) enrollment and timelines while TTR sales growth dominates Alnylam estimates.
▼ NAMS NewAmsterdam Pharma — impact -35 · confidence low · horizon weeks · 2nd order
NewAmsterdam must rely entirely on LDL outcomes for obicetrapib because its secondary Lp(a) lowering claim loses pricing weight.
Chain: Lp(a) lowering benefit unproven after pelacarsen miss → obicetrapib secondary Lp(a) claim loses marketing weight → payer pricing rests only on LDL outcomes → NewAmsterdam differentiation and pricing power narrow
What would break the call: PREVAIL LDL outcomes data hits its endpoint strongly and payers price obicetrapib on that alone.
▼ LLY Eli Lilly — impact -24 · confidence medium · horizon immediate · 2nd order
Lilly's lepodisiran and muvalaplin lose projected value because pelacarsen failed to show that Lp(a) reduction prevents heart attacks.
Chain: Lp(a) causal hypothesis loses outcomes validation → lepodisiran and muvalaplin success odds fall → ACCLAIM outcomes program risk repriced → Lilly cardiometabolic pipeline value written down
What would break the call: Lepodisiran shows deeper sustained Lp(a) reduction and Lilly reaffirms full outcomes trial enrollment.
▼ RPRX Royalty Pharma — impact -22 · confidence low · horizon immediate · 2nd order
Royalty Pharma loses upside from its pelacarsen royalty interest as failed outcomes data reduces approval and sales prospects.
Chain: Royalty Pharma holds pelacarsen royalty interest → approval and launch probability collapses after miss → expected royalty cash flows written down → portfolio net asset value reduced
What would break the call: Disclosure shows minimal capital deployed on pelacarsen with milestones already recovered by Royalty Pharma.
▼ ARWR Arrowhead Pharmaceuticals — impact -20 · confidence low · horizon quarters · 3rd order
Arrowhead negotiates cardiometabolic partnerships with buyers who now demand outcomes proof before paying large upfront amounts.
Chain: cardiometabolic siRNA class credibility damaged → pharma buyers demand outcomes evidence before deals → Arrowhead upfront and milestone terms weaken → platform financing and partnership revenue pressured
What would break the call: Arrowhead signs a large cardiometabolic license with a substantial upfront in the coming quarters.
▼ DGX Quest Diagnostics — impact -15 · confidence low · horizon quarters · 2nd order
Quest Diagnostics loses the testing volume growth that broad Lp(a) screening would have driven through cardiology referrals.
Chain: pelacarsen fails to prove Lp(a) lowering benefit → guidelines delay universal Lp(a) screening push → cardiology test ordering growth stalls → Quest specialty testing volume upside removed
What would break the call: Guidelines still mandate one time Lp(a) testing for risk stratification and screening volumes rise anyway.
▼ LH Labcorp — impact -15 · confidence low · horizon quarters · 2nd order
Labcorp faces slower adoption of Lp(a) panels because clinicians order such tests mainly when treatment exists.
Chain: no approved therapy targets elevated Lp(a) → clinicians order fewer Lp(a) panels → Labcorp esoteric test volume growth slows → diagnostics revenue upside case weakens
What would break the call: Cardiology societies expand Lp(a) testing recommendations for risk assessment and panel volumes still climb.
▼ IQV IQVIA — impact -12 · confidence low · horizon quarters · 3rd order
IQVIA loses potential contract research work as sponsors pause large Lp(a) outcomes trials after the class setback.
Chain: Lp(a) mechanism validation fails → sponsors reassess large cardiovascular outcomes programs → planned trial starts delayed or cancelled → clinical research bookings soften
What would break the call: Sponsors expand other cardiometabolic outcomes trials and IQVIA bookings growth continues unchanged.
▼ TMO Thermo Fisher Scientific — impact -8 · confidence low · horizon quarters · 3rd order
Thermo Fisher sells assay reagents and trial services tied to Lp(a) programs that now slow or stop.
Chain: Lp(a) drug programs deprioritized after failure → demand for related assays and trial services falls → pharma services and diagnostics orders soften → Thermo revenue growth marginally trimmed
What would break the call: Broader pharma research spending recovery lifts Thermo orders and masks any Lp(a) related decline.

Already moved

▲ MRK Merck — impact +32 · confidence medium · horizon quarters · 2nd order
Merck gains cardiovascular prescription volume and pricing power because pelacarsen's failure reduces competition for its oral PCSK9 therapy.
Chain: pelacarsen removed from future prevention launches → fewer injectable competitors for residual risk patients → enlicitide oral PCSK9 faces thinner competitive field → Merck cardiometabolic launch revenue estimates improve
What would break the call: Enlicitide outcomes or safety data disappoints, removing the competitive benefit from the field clearing.
▲ REGN Regeneron — impact +30 · confidence medium · horizon quarters · 3rd order
Regeneron's Praluent gains revenue as pelacarsen's failed outcomes trial reduces competition among lipid-lowering therapies.
Chain: Lp(a) injectable class setback delays new entrants → PCSK9 antibodies keep residual risk patients longer → Praluent prescription volumes hold up → Regeneron collaboration revenue modestly supported
What would break the call: Oral PCSK9 approvals or generic statin plus ezetimibe pressure erode Praluent scripts regardless of pelacarsen.
▲ AZN AstraZeneca — impact +25 · confidence low · horizon quarters · 3rd order
AstraZeneca develops an oral PCSK9 candidate that now competes against fewer credible cardiovascular prevention launches later this decade.
Chain: pelacarsen exits future cardiovascular prevention market → competitive field for lipid launches thins → AstraZeneca oral PCSK9 candidate gains relative room → later decade cardiovascular revenue outlook improves
What would break the call: AZD0780 fails to show competitive LDL lowering or Merck reaches market first with better data.
▲ SNY Sanofi — impact +25 · confidence low · horizon quarters · 3rd order
Sanofi lipid drug pricing power improves when the phase three miss eliminates a potential market rival.
Chain: Lp(a) prevention entrant removed from market → Praluent faces fewer future substitutes → Sanofi lipid franchise pricing power holds → modest support to specialty care revenue
What would break the call: Payer formulary shifts to cheap oral generics compress Praluent pricing independent of the pelacarsen result.
▲ ABT Abbott — impact +20 · confidence low · horizon quarters · 3rd order
Abbott sells stents and cardiac diagnostics into a population whose atherosclerotic event rate stays high without new lipoprotein therapy.
Chain: no new preventive therapy for elevated Lp(a) → residual atherosclerotic event rate stays elevated → stent and cardiac diagnostic demand persists → Abbott vascular revenue outlook protected
What would break the call: Oral PCSK9 or other prevention approvals cut event rates and procedure volumes anyway.
▲ BSX Boston Scientific — impact +20 · confidence low · horizon quarters · 3rd order
Boston Scientific retains interventional cardiology procedure volumes that an effective preventive injectable would have eroded over coming years.
Chain: preventive Lp(a) injectable fails outcomes test → future reduction in ischemic events does not arrive → interventional cardiology procedure volumes hold → Boston Scientific device revenue outlook steady
What would break the call: Hospital staffing limits or reimbursement cuts cap procedure growth regardless of drug outcomes.
▲ AMRN Amarin — impact +18 · confidence low · horizon quarters · 3rd order
Amarin promotes Vascepa for residual cardiovascular risk, a niche that stays open after the rival lowering strategy failed.
Chain: residual cardiovascular risk remains unaddressed → competing risk reduction narrative loses credibility → Vascepa positioning in residual risk stays viable → Amarin prescription volume decline pressure eases
What would break the call: Continued generic icosapent ethyl competition drives Vascepa revenue lower irrespective of the trial news.
▲ MDT Medtronic — impact +18 · confidence low · horizon quarters · 3rd order
Medtronic keeps coronary and peripheral device demand because untreated residual risk continues generating procedures in catheterization labs.
Chain: no new preventive Lp(a) therapy reaches market → atherosclerotic disease progression continues in high risk patients → coronary and peripheral intervention demand persists → Medtronic device volumes protected
What would break the call: Medtronic vascular share losses to rivals overwhelm any procedure volume benefit.
▲ CI Cigna — impact +15 · confidence low · horizon quarters · 3rd order
Cigna avoids underwriting an expensive lifelong injectable for millions of screened patients, keeping specialty pharmacy trend lower.
Chain: expensive lifelong injectable does not reach market → specialty pharmacy prevention spending avoided → Evernorth drug trend stays lower → Cigna medical cost ratio pressure eased
What would break the call: Oral PCSK9 launches at scale and drives the same specialty prevention spending increase.
▲ NVO Novo Nordisk — impact +15 · confidence low · horizon quarters · 3rd order
Novo's ziltivekimab targets inflammation rather than Lp(a) and gains relative standing as a differentiated cardiovascular prevention mechanism.
Chain: Lp(a) lowering fails as prevention mechanism → attention shifts to inflammation pathway assets → ziltivekimab competitive position improves → Novo cardiovascular pipeline value supported
What would break the call: Ziltivekimab outcomes trials miss their endpoints, removing the pipeline benefit entirely.
▲ OGN Organon — impact +15 · confidence low · horizon quarters
Organon markets Zetia and Vytorin into a market where cheap LDL lowering remains the default prevention spend.
▲ HCA HCA Healthcare — impact +12 · confidence low · horizon quarters · 3rd order
HCA cardiac catheterization and surgical volumes persist because no new preventive therapy reduces future ischemic event rates.
Chain: preventive Lp(a) therapy fails outcomes trial → high risk patients keep having cardiac events → hospital cardiology admissions and procedures continue → HCA surgical revenue mix protected
What would break the call: Payer site of care shifts move cardiac procedures to ambulatory centers away from hospitals.

Sources

What happened

Horizon	Verdict	Top pick	Excess vs SPY
1 trading days	Mixed	MRK	-0.7% vs SPY
5 trading days	Wrong	MRK	-2.4% vs SPY

Related scenarios

Stocks in this scenario

IONS · NVS · AMGN · SLN · ALNY · NAMS · LLY · RPRX · ARWR · DGX · LH · IQV · TMO · MRK · REGN · AZN · SNY · ABT · BSX · AMRN · MDT · CI · NVO · OGN · HCA

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario